Surrozen Inc (SRZN) Stock Analysis
Verdict: AVOID
Surrozen offers high-risk clinical Wnt-pathway pipeline exposure, but a 108% unbacked price spike exposes buyers to severe downside.
Investment score: 37/100
Analysis as of
Is Surrozen Inc stock worth reviewing? The TradeMates thesis
The model views Surrozen as an AVOID at $33.68 USD following an unbacked 108.4% single-day rally. Fundamental balance sheet deficits and extreme earnings volatility offset clinical pipeline potential.
7-factor investment score
- Valuation: 20/100 (weight 20%)
- Financial Health: 45/100 (weight 15%)
- Technical Momentum: 65/100 (weight 15%)
- Earnings Quality: 20/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 70/100 (weight 10%)
- Risk-Adjusted Return: 25/100 (weight 15%)
Surrozen Inc opportunities and risks
What speaks for SRZN
- Boehringer Ingelheim strategic partnership validation
What speaks against SRZN
- Extreme retracement risk post-squeeze
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| SRZN | n/a | 21.9x | n/a | 99.4% | -2885.3% | -13.9% |
| FHTX | n/a | 5.8x | n/a | 42.7% | -175.8% | -40.4% |
| WHWK | n/a | 0.0x | n/a | 0.0% | 0.0% | -31.5% |
| CMPX | n/a | 0.0x | n/a | 0.0% | 0.0% | -26.9% |
| NKTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -46.1% |
| TARA | n/a | 0.0x | n/a | 0.0% | 0.0% | -34.6% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -34.6% |
Frequently asked questions about Surrozen Inc (SRZN)
Is SRZN stock a good investment?
The TradeMates model rates Surrozen Inc as AVOID with an investment score of 37/100. The model views Surrozen as an AVOID at $33.68 USD following an unbacked 108.4% single-day rally. Fundamental balance sheet deficits and extreme earnings volatility offset clinical pipeline potential. This is algorithmic model output, not personal investment advice.
Is SRZN stock a buy?
The TradeMates model verdict for SRZN is AVOID with an investment score of 37/100. Treat this as a model signal to review, not a personal buy recommendation.